Kymera Therapeutics (KYMR) Other Non-Current Liabilities (2020 - 2023)

Kymera Therapeutics (KYMR) has 4 years of Other Non-Current Liabilities data on file, last reported at $8000.0 in Q3 2023.

• Other Non-Current Liabilities for Q3 2023 came in at $8000.0, down 96.88% year-over-year; the trailing twelve-month figure through Sep 2023 was $8000.0 (down 96.88% YoY), and the FY2022 annual result was $248000.0, up 275.76% from the prior year.
• Other Non-Current Liabilities fell to $8000.0 in Q3 2023 per KYMR's latest filing, from $230000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $273000.0 in Q1 2022 and troughed at $8000.0 in Q3 2023.
• A 4-year average of $161166.7 and a median of $165000.0 in 2020 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 275.76% in 2022, then plunged 96.88% in 2023.
• A 4-year view of Other Non-Current Liabilities shows it stood at $100000.0 in 2020, then slumped by 34.0% to $66000.0 in 2021, then soared by 275.76% to $248000.0 in 2022, then tumbled by 96.77% to $8000.0 in 2023.
• Business Quant data shows KYMR's Other Non-Current Liabilities at $8000.0 in Q3 2023, $230000.0 in Q2 2023, and $237000.0 in Q1 2023.